B 2069
Alternative Names: B-2069Latest Information Update: 25 Jul 2022
At a glance
- Originator Tasly Biopharmaceuticals
- Class Anti-inflammatories; Bispecific antibodies
- Mechanism of Action Complement system protein inhibitors; Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Autoimmune disorders; Systemic lupus erythematosus
Most Recent Events
- 20 Jul 2022 Preclinical trials in Amyotrophic lateral sclerosis in China (Parenteral), before July 2022
- 20 Jul 2022 Preclinical trials in Autoimmune disorders in China (Parenteral), before July 2022
- 20 Jul 2022 Preclinical trials in Systemic lupus erythematosus in China (Parenteral), before July 2022